Antibiotic therapy during labour – the Slovenian recomendations
DOI:
https://doi.org/10.6016/ZdravVestn.2916Keywords:
antibiotic prophylaxis, group B streptococci (GBS), preterm labour, preterm premature rupture of membranes (PPROM), recommendationsAbstract
Antibiotic agents are administered during the intrapartum period to prevent and treat maternal infection and to prevent neonatal disease. Short courses of antibiotics are used during labour to prevent such infections as group B streptococci (GBS) in newborns, postpartum endometritis and to treat chorioamnionitis. Many trials have evaluated the use of prophylactic antibiotics to prolong the pregnancy (and subsequently improve neonatal outcomes) after premature rupture of membranes (PROM).
Intravenous antibiotics recommended for women in active preterm labour are: Penicillin G: given initially as 3 g (or 5MU) intravenously and then 1.5 g (or 2.5MU) at 4-hour intervals until delivery. For women allergic to penicillin: provided a woman has not had severe allergy to penicillin, a cephalosporin should be used. If there is any evidence of severe allergy to penicillin, vancomycin should be used. For women allergic to penicillin, Clindamycin is no longer recommended as the current resistance rate is high.
Where infection of the membranes is diagnosed or suspected or where there is preterm prolonged rupture of membranes, broad-spectrum intravenous antibiotics should be given, which include adequate GBS cover (we recommend Cefazolin 2 g i.v and then 1 g at 8-hour intervals until delivery).
In PPROM we recommend as soon as possible after PPROM: ampicillin (2 g i.v. every 6 hours) for 48 hours plus azithromycin (1 g po in onetime administration), followed by amoxicillin (500 mg po every 8 hours) for 5 days unless delivery occurs.
Downloads
References
1. Royal College of Obstetricians and GynecologistsThe Prevention of Early-onset neonatal Group B Streptococcal Disease. Green-top guideline No. 36 July 2012. London: Royal College of Obstetricians and Gynecologist; 2012.
2. Society of Obstetricians and Gynaecologists of CanadaThe Prevention of Early-Onset Neonatal Group B Streptococcal Disease. Ottawa: Society of Obstetricians and Gynaecologists of Canada; 2013.
3. Royal Australian and New Zealand College of Obstetricians and GynaecologistsScreening and Treatment for Group B Streptococcus in Pregnancy. Melbourne: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2012.
4. Regan JA, Klebanoff MA, Nugent RP; Vaginal Infections and Prematurity Study Group. The epidemiology of group B streptococcal colonization in pregnancy. Obstet Gynecol. 1991;77(4):604-10.
PMID: 2002986
5. Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr. 1973;83(6):919-25.
DOI: 10.1016/S0022-3476(73)80524-4
PMID: 4585831
6. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59:1-36.
PMID: 21088663
7. Baker CJ, Byington CL, Polin RA; Committee on Infectious Diseases; Committee on Fetus and Newborn. Policy statement—recommendations for the prevention of perinatal group B streptococcal (GBS) disease. Pediatrics. 2011;128(3):611-6.
PMID: 21807694
8. Regan JA, Klebanoff MA, Nugent RP, Eschenbach DA, Blackwelder WC, Lou Y, et al.; VIP Study Group. Colonization with group B streptococci in pregnancy and adverse outcome. Am J Obstet Gynecol. 1996;174(4):1354-60.
DOI: 10.1016/S0002-9378(96)70684-1
PMID: 8623869
9. Allen VM, Yudin MH; Infectious Diseases Committee. Management of group B streptococcal bacteriuria in pregnancy. J Obstet Gynaecol Can. 2012;34(5):482-6.
DOI: 10.1016/S1701-2163(16)35246-X
PMID: 22555143
10. Schwope OI, Chen KT, Mehta I, Re M, Rand L. The effect of a chlorhexidine-based surgical lubricant during pelvic examination on the detection of group B Streptococcus. Am J Obstet Gynecol. 2010;202(3):276.e1-3.
DOI: 10.1016/j.ajog.2009.10.860
PMID: 20022579
11. Price D, Shaw E, Howard M, Zazulak J, Waters H, Kaczorowski J. Self-sampling for group B streptococcus in women 35 to 37 weeks pregnant is accurate and acceptable: a randomized cross-over trial. J Obstet Gynaecol Can. 2006;28(12):1083-8.
DOI: 10.1016/S1701-2163(16)32337-4
PMID: 17169231
12. Honest H, Sharma S, Khan KS. Rapid tests for group B Streptococcus colonization in laboring women: a systematic review. Pediatrics. 2006;117(4):1055-66.
DOI: 10.1542/peds.2005-1114
PMID: 16585299
13. Gardner SE, Yow MD, Leeds LJ, Thompson PK, Mason EO, Clark DJ. Failure of penicillin to eradicate group B streptococcal colonization in the pregnant woman. A couple study. Am J Obstet Gynecol. 1979;135(8):1062-5.
DOI: 10.1016/0002-9378(79)90737-3
PMID: 391044
14. Ramus RM, McIntire DD, Wendel GD. Antibiotic chemoprophylaxis for group B strep is not necessary with elective cesarean section at term. Am J Obstet Gynecol. 1999;180:S85.
15. Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol. 1998;92(2):258-61.
PMID: 9699763
16. Baecher L, Grobman W. Prenatal antibiotic treatment does not decrease group B streptococcus colonization at delivery. Int J Gynaecol Obstet. 2008;101(2):125-8.
DOI: 10.1016/j.ijgo.2007.10.012
PMID: 18082163
17. Fairlie T, Zell ER, Schrag S. Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. Obstet Gynecol. 2013;121(3):570-7.
DOI: 10.1097/AOG.0b013e318280d4f6
PMID: 23635620
18. Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev. 2014;6(6):CD007467.
DOI: 10.1002/14651858.CD007467.pub4
PMID: 24915629
19. Sinha A, Yokoe D, Platt R. Intrapartum antibiotics and neonatal invasive infections caused by organisms other than group B streptococcus. J Pediatr. 2003;142(5):492-7.
DOI: 10.1067/mpd.2003.154
PMID: 12756379
20. Schrag SJ, Hadler JL, Arnold KE, Martell-Cleary P, Reingold A, Schuchat A. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. Pediatrics. 2006;118(2):570-6.
DOI: 10.1542/peds.2005-3083
PMID: 16882809
21. Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin North Am. 2005;32(3):411-28.
DOI: 10.1016/j.ogc.2005.03.003
PMID: 16125041
22. Melamed N, Hadar E, Ben-Haroush A, Kaplan B, Yogev Y. Factors affecting the duration of the latency period in preterm premature rupture of membranes. J Matern Fetal Neonatal Med. 2009;22(11):1051-6.
DOI: 10.3109/14767050903019650
PMID: 19900043
23. Practice bulletins No. 139: premature rupture of membranes. Obstet Gynecol. 2013;122(4):918-30.
DOI: 10.1097/01.AOG.0000435415.21944.8f
PMID: 24084566
24. van der Ham DP, van der Heyden JL, Opmeer BC, Mulder AL, Moonen RM, van Beek JH, et al. Management of late-preterm premature rupture of membranes: the PPROMEXIL-2 trial. Am J Obstet Gynecol. 2012;207(4):276.e1-10.
DOI: 10.1016/j.ajog.2012.07.024
PMID: 22901981
25. Al-Mandeel H, Alhindi MY, Sauve R. Effects of intentional delivery on maternal and neonatal outcomes in pregnancies with preterm prelabour rupture of membranes between 28 and 34 weeks of gestation: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2013;26(1):83-9.
DOI: 10.3109/14767058.2012.718388
PMID: 22882130
26. Buchanan SL, Crowther CA, Levett KM, Middleton P, Morris J. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks’ gestation for improving pregnancy outcome. Cochrane Database Syst Rev. 2010(3):CD004735.
DOI: 10.1002/14651858.CD004735.pub3
PMID: 20238332
27. van der Ham DP, Vijgen SM, Nijhuis JG, van Beek JJ, Opmeer BC, Mulder AL, et al.; PPROMEXIL trial group. Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks: a randomized controlled trial. PLoS Med. 2012;9(4):e1001208.
DOI: 10.1371/journal.pmed.1001208
PMID: 22545024
28. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2013;12:CD001058.
DOI: 10.1002/14651858.CD004454.pub2
PMID: 16856047
29. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2013;12:CD001058.
30. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1-110.
PMID: 21160459
31. Pierson RC, Gordon SS, Haas DM. A retrospective comparison of antibiotic regimens for preterm premature rupture of membranes. Obstet Gynecol. 2014;124(3):515-9.
DOI: 10.1097/AOG.0000000000000426
PMID: 25162251
32. Mercer BM. PPROM: current approaches to evalutation and management. Obstet Gynecol Clin North Am. 2005;32:411.
DOI: 10.1016/j.ogc.2005.03.003
PMID: 16125041
33. Hutzal CE, Boyle EM, Kenyon SL, Nash JV, Winsor S, Taylor DJ, et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol. 2008;199(6):620.e1-8.
DOI: 10.1016/j.ajog.2008.07.008
PMID: 18973872
34. ACOG Committee Opinion NoACOG Committee Opinion No. 445: antibiotics for preterm labor. Obstet Gynecol. 2009;114(5):1159-60.
DOI: 10.1097/AOG.0b013e3181c33c86
PMID: 20168128
35. Pierson RC, Gordon SS, Haas DM. A retrospective comparison of antibiotic regimens for preterm premature rupture of membranes. Obstet Gynecol. 2014;124(3):515-9.
DOI: 10.1097/AOG.0000000000000426
PMID: 25162251
36. Grigsby PL, Novy MJ, Sadowsky DW, Morgan TK, Long M, Acosta E, et al. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol. 2012;207(6):475.e1-14.
DOI: 10.1016/j.ajog.2012.10.871
PMID: 23111115
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
